Produktbeschreibung
Indikationen
BARUDX Janus (JAK) ， • TNF JAK DMARD • (ECMO) COVID-19 • JAK
Wirkmechanismus
Immunosuppressants baricitinib
Pharmakologie
Immunosuppressants EMA Rheumatoid arthritis Baricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Olumiant may be used as monotherapy or in combination with methotrexate. Atopic Dermatitis Olumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older
Dosierung
• Volle Details ， •
Nebenwirkungen
≥1% • (URTI) • (COVID-19) (UTI) •
